These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 21921261

  • 1. N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study.
    Doi Y, Ninomiya T, Hata J, Hirakawa Y, Mukai N, Ikeda F, Fukuhara M, Iwase M, Kiyohara Y.
    Arterioscler Thromb Vasc Biol; 2011 Dec; 31(12):2997-3003. PubMed ID: 21921261
    [Abstract] [Full Text] [Related]

  • 2. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR.
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [Abstract] [Full Text] [Related]

  • 3. Glomerular filtration rate and N-terminal pro-brain natriuretic peptide as predictors of cardiovascular mortality in vascular patients.
    Shadman R, Allison MA, Criqui MH.
    J Am Coll Cardiol; 2007 Jun 05; 49(22):2172-81. PubMed ID: 17543637
    [Abstract] [Full Text] [Related]

  • 4. Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort aged ≥ 70 years.
    Eggers KM, Venge P, Lind L.
    Am J Cardiol; 2013 Jan 01; 111(1):131-6. PubMed ID: 23040598
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.
    Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR.
    J Hypertens; 2008 Jan 01; 26(1):26-34. PubMed ID: 18090537
    [Abstract] [Full Text] [Related]

  • 6. Sex-specific threshold levels of plasma B-type natriuretic peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease.
    Nakamura M, Tanaka F, Takahashi T, Makita S, Ishisone T, Onodera M, Ishibashi Y, Itai K, Onoda T, Ohsawa M, Tanno K, Sakata K, Shinichi O, Ogasawara K, Ogawa A, Kuribayashi T, Okayama A.
    Am J Cardiol; 2011 Dec 01; 108(11):1564-9. PubMed ID: 21871591
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
    Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, Lin SJ.
    Coron Artery Dis; 2008 May 01; 19(3):187-93. PubMed ID: 18418236
    [Abstract] [Full Text] [Related]

  • 8. [N-terminal pro brain natriuretic peptide predicts hospitalization of hemodialysis patients for cardiovascular disease].
    Naito T, Masaki T, Shimizu Y, Ogawa T, Ochiai M, Hamaguchi N, Hirashio S, Doi T, Yokoyama Y, Yorioka N.
    Nihon Jinzo Gakkai Shi; 2011 May 01; 53(4):633-41. PubMed ID: 21688486
    [Abstract] [Full Text] [Related]

  • 9. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
    Berg T, Zdunek D, Stalke J, Dupke S, Baumgarten A, Carganico A, Hess G.
    Eur J Med Res; 2007 Apr 26; 12(4):152-60. PubMed ID: 17509959
    [Abstract] [Full Text] [Related]

  • 10. The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
    Goei D, Flu WJ, Hoeks SE, Galal W, Dunkelgrun M, Boersma E, Kuijper R, van Kuijk JP, Winkel TA, Schouten O, Bax JJ, Poldermans D.
    Anesth Analg; 2009 Nov 26; 109(5):1403-8. PubMed ID: 19843778
    [Abstract] [Full Text] [Related]

  • 11. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
    Rothenbacher D, Koenig W, Brenner H.
    Arch Intern Med; 2009 Nov 26; 166(22):2455-60. PubMed ID: 17159010
    [Abstract] [Full Text] [Related]

  • 12. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1973-80. PubMed ID: 17996563
    [Abstract] [Full Text] [Related]

  • 13. Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
    Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS.
    N Engl J Med; 2004 Feb 12; 350(7):655-63. PubMed ID: 14960742
    [Abstract] [Full Text] [Related]

  • 14. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.
    Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW.
    Circulation; 2005 Jul 05; 112(1):110-6. PubMed ID: 15983245
    [Abstract] [Full Text] [Related]

  • 15. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E.
    Am J Cardiol; 2008 Sep 15; 102(6):733-7. PubMed ID: 18773998
    [Abstract] [Full Text] [Related]

  • 16. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Münzel T, Yusuf S, HOPE Study Investigators.
    Circulation; 2006 Jul 18; 114(3):201-8. PubMed ID: 16831981
    [Abstract] [Full Text] [Related]

  • 17. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.
    West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, Pollicino C, Lubos E, Münzel TF, White HD, Tonkin AM, Bickel C, Tiret L, Blankenberg S, LIPID Study Investigators.
    Eur Heart J; 2008 Apr 18; 29(7):923-31. PubMed ID: 18296678
    [Abstract] [Full Text] [Related]

  • 18. N-terminal pro B-type natriuretic peptide identifies patients with chest pain at high long-term cardiovascular risk.
    van der Zee PM, Cornel JH, Bholasingh R, Fischer JC, van Straalen JP, De Winter RJ.
    Am J Med; 2011 Oct 18; 124(10):961-9. PubMed ID: 21962317
    [Abstract] [Full Text] [Related]

  • 19. Urinary N-terminal pro-B-type natriuretic peptide as a biomarker for cardiovascular events in a general Japanese population: the Hisayama Study.
    Yamasaki K, Hata J, Ide T, Nagata T, Sakata S, Yoshida D, Honda T, Hirakawa Y, Nakano T, Kitazono T, Tsutsui H, Ninomiya T.
    Environ Health Prev Med; 2021 Apr 12; 26(1):47. PubMed ID: 33845756
    [Abstract] [Full Text] [Related]

  • 20. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.
    Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR.
    Eur Heart J; 2007 Jun 12; 28(11):1374-81. PubMed ID: 17242007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.